Brief: Ipsen To Buy Kartos Therapeutics In Definitive Merger Agreement
29/06/2026 06:03
BRIEF-Ipsen To Buy Kartos Therapeutics In Definitive Merger Agreement June 29 (Reuters) - Ipsen SA IPN.PA:
TO BUY KARTOS THERAPEUTICS IN DEFINITIVE MERGER AGREEMENT
IPSEN TO ACQUIRE KARTOS THERAPEUTICS, EXPANDING HEMATO-ONCOLOGY LATE-STAGE PIPE
TO PAY $450 MILLION UPFRONT FOR KARTOS THERAPEUTICS ACQUISITION
DEAL EXPECTED TO CLOSE BY END OF Q3 2026
DEAL EXPECTED TO BE ACCRETIVE TO IPSEN CORE OPERATING INCOME FROM 2029
TOP-LINE DATA FROM PHASE III POIESIS TRIAL EXPECTED IN 2027
KARTOS SHAREHOLDERS ELIGIBLE FOR UP TO $1.3 BILLION IN MILESTONE PAYMENTS
ACQUISITION ADDS PHASE III NAVTEMADLIN TO IPSEN ONCOLOGY PORTFOLIO
Source text: ID:nGNE4jFx9G
Further company coverage: IPN.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ipsen SA
See all newsHealth Rounds: New blood test matches gold standard for liver disease diagnosis
Brief: Ipsen Late-Breaking Data Raises Ambitions In PBC
Brief: Charles River Laboratories International Virtual Control Group To Be Used In Glp Study For Ipsen
Pharming shares rise after preliminary Q3 revenue beat
France's Ipsen Q3 sales rise 28% driven by core portfolio